<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078736</url>
  </required_header>
  <id_info>
    <org_study_id>REC/Lhr/0409 Shama</org_study_id>
    <nct_id>NCT05078736</nct_id>
  </id_info>
  <brief_title>Effects of Moderate Intensity Intermittent and Moderate Intensity Continuous Training on Hyperlipdemia</brief_title>
  <official_title>Effects of Moderate Intensity Intermittent Training Versus Continuous Training on Indices of Cardio-metabolic Health in Women With Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Riphah International University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Riphah International University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will be a Randomized control trial conducted to check the effects of moderate&#xD;
      intensity intermittent training versus moderate intensity continuous training on indices of&#xD;
      cardio-metabolic health in women with hyperlipidemia, duration will be of 5 weeks, purposive&#xD;
      sampling data technique, will be done, subject following eligibility criteria from milestone&#xD;
      gym Sialkot, will randomly allocated in two groups via lottery method, baseline assessment&#xD;
      will be done, Group A participants will receive baseline treatment along with moderate&#xD;
      intensity intermittent training, and Group B participants will receive baseline treatment&#xD;
      along with moderate intensity continuous training. Pre and post intervention assessment will&#xD;
      include lipid profile test and Vo2 max rating of perceived exertion (RPE), and post data will&#xD;
      be analyzed by using SPSS version 25.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperlipidemia is a condition with high levels of fat in the blood, such as cholesterol and&#xD;
      triglycerides. Hyperlipidemia is most commonly associated with high-fat diets, sedentary&#xD;
      lifestyle, obesity and diabetes. The aim of the current study is to find the effectiveness of&#xD;
      moderate intensity intermittent training and moderate intensity continuous training in women&#xD;
      with hyperlipidemia. It will be a Randomized control trial and screening will be done as per&#xD;
      the inclusion criteria of women having 30-40 years of age with hyperlipidemia. Participants&#xD;
      with the history of any serious cardiac condition, musculoskeletal injury, and any type of&#xD;
      systemic issue will be excluded.&#xD;
&#xD;
      Participants will be randomly allocated into two groups, Group A will receive moderate&#xD;
      intensity intermittent training consist of running for 5 km with 1-min at 70% of maximal&#xD;
      aerobic speed with interval of 1-min passive recovery and Group B will receive moderate&#xD;
      intensity continuous training consist of running continuously for 5 km at 70% of maximal&#xD;
      aerobic speed for 5 weeks including exercise training of 3 days/week. Participants in both&#xD;
      groups will be assessed with Lipid profile (fasting triglycerides, High Density Lipoproteins,&#xD;
      Low density Lipoproteins) before and after the intervention.&#xD;
&#xD;
      VO2 max, rating of perceived exertion (RPE) Step Test: The step test is designed to measure a&#xD;
      person's aerobic fitness. Participants step up and down, on and off an aerobic- type step for&#xD;
      three minutes to increase heart rate and evaluate the heart's recovery rate during the minute&#xD;
      immediately following the step test exercise.&#xD;
&#xD;
      Modified Borg scale: MBS is a 0-10 rated numerical score used to measure dyspnea as reported&#xD;
      by the patient during submaximal exercise and is routinely administrated during six-minute&#xD;
      walk testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>5 weeks</time_frame>
    <description>Lipid profile (fasting triglycerides, HDL, LDL) will be done through blood samples of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Step Test:</measure>
    <time_frame>5th Week</time_frame>
    <description>The step test is designed to measure a person's aerobic fitness. Participants step up and down, on and off an aerobic- type step for three minutes to increase heart rate and evaluate the heart's and evaluate the heart's recovery rate during the minute immediately following the step test exercise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Borg scale</measure>
    <time_frame>5th Week</time_frame>
    <description>MBS is a 0-10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and is routinely administrated during six-minute walk testing.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>moderate intensity intermittent training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>baseline physical therapy treatment along with moderate intensity intermittent training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>moderate intensity continuous training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>baseline physical therapy treatment along with moderate intensity continuous training</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Moderate intensity intermittent training</intervention_name>
    <description>In group A participants will receive moderate intensity intermittent training including running of 5 km with 1-min at 70% of maximal aerobic speed with interval of 1-min passive recovery, exercises will be performed by gym trainer for 5 weeks including 3 days/week</description>
    <arm_group_label>moderate intensity intermittent training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Moderate intensity continuous training</intervention_name>
    <description>In group B participants will receive moderate intensity continuous training ran continuously the same 5 km at 70% of maximal aerobic speed, exercises will be performed by gym trainer for 5 weeks including 3 days/week.</description>
    <arm_group_label>moderate intensity continuous training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women.&#xD;
&#xD;
          -  Age 30-40 years.&#xD;
&#xD;
          -  Hyperlipidemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With another serious cardiac condition.&#xD;
&#xD;
          -  With any musculoskeletal injury.&#xD;
&#xD;
          -  With any systematic condition.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Syed Shakil Ur Rehman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Riphah International University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Imran Amjad</last_name>
    <phone>03324390125</phone>
    <email>imran.amjad@riphah.edu.pk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sialkot, Milestone gym</name>
      <address>
        <city>Sialkot</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syed Shakil Ur Rehman</last_name>
      <phone>0320-7866611</phone>
      <email>shakil.urrehman@riphah.edu.pk</email>
    </contact>
    <investigator>
      <last_name>Shama Zulfiqar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Nirosha K, Divya M, Vamsi S, Sadiq M. A review on hyperlipidemia. International Journal of Novel Trends in PharmaceuticalSciences. 2014;4(5):81-92</citation>
  </reference>
  <reference>
    <citation>Fung M, Hill J, Cook D, Frohlich J. Case series of type III hyperlipoproteinemia in children. BMJ Case Rep. 2011 Jun 9;2011. pii: bcr0220113895. doi: 10.1136/bcr.02.2011.3895.</citation>
    <PMID>22691586</PMID>
  </reference>
  <reference>
    <citation>Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S; Committee for Epidemiology and Clinical Management of Atherosclerosis. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb. 2018 Sep 1;25(9):846-984. doi: 10.5551/jat.GL2017. Epub 2018 Aug 22.</citation>
    <PMID>30135334</PMID>
  </reference>
  <reference>
    <citation>Zhang ZH, Wei F, Vaziri ND, Cheng XL, Bai X, Lin RC, Zhao YY. Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis. Sci Rep. 2015 Sep 28;5:14472. doi: 10.1038/srep14472.</citation>
    <PMID>26412413</PMID>
  </reference>
  <reference>
    <citation>Álvarez Ramírez AA, Peláez JL, Bermúdez IM, Gordon Botero JY. Prevalence of hyperlipidemia and its associated factors in university students in Colombia. Heliyon. 2020 Nov 3;6(11):e05417. doi: 10.1016/j.heliyon.2020.e05417. eCollection 2020 Nov.</citation>
    <PMID>33195846</PMID>
  </reference>
  <reference>
    <citation>Abid N, Khan SA, Taseer I. Frequency of hyperlipidemia in patients presenting with ischemic stroke. Pak J Med Health Sci. 2012;6(2):423-28</citation>
  </reference>
  <reference>
    <citation>Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013 Mar;40(1):195-211. doi: 10.1016/j.pop.2012.11.003. Epub 2012 Dec 4. Review.</citation>
    <PMID>23402469</PMID>
  </reference>
  <reference>
    <citation>Caballero B, Trugo LC, Finglas PM. Encyclopedia of food sciences and nutrition: Academic; 2003</citation>
  </reference>
  <reference>
    <citation>Pramparo P, Boissonnet C, Schargrodsky H. Evaluation of Cardiovascular Risk in Seven Cities in Latin America: The Main Conclusions. Argentine Journal of Cardiology.79(4):368-70</citation>
  </reference>
  <reference>
    <citation>Lira FS, Antunes BM, Figueiredo C, Campos EZ, Panissa VLG, St-Pierre DH, Lavoie JM, Magri-Tomaz L. Impact of 5-week high-intensity interval training on indices of cardio metabolic health in men. Diabetes Metab Syndr. 2019 Mar - Apr;13(2):1359-1364. doi: 10.1016/j.dsx.2019.02.006. Epub 2019 Feb 5.</citation>
    <PMID>31336492</PMID>
  </reference>
  <reference>
    <citation>Alansare A, Alford K, Lee S, Church T, Jung HC. The Effects of High-Intensity Interval Training vs. Moderate-Intensity Continuous Training on Heart Rate Variability in Physically Inactive Adults. Int J Environ Res Public Health. 2018 Jul 17;15(7). pii: E1508. doi: 10.3390/ijerph15071508.</citation>
    <PMID>30018242</PMID>
  </reference>
  <reference>
    <citation>Khan SU, Khan MZ, Raghu Subramanian C, Riaz H, Khan MU, Lone AN, Khan MS, Benson EM, Alkhouli M, Blaha MJ, Blumenthal RS, Gulati M, Michos ED. Participation of Women and Older Participants in Randomized Clinical Trials of Lipid-Lowering Therapies: A Systematic Review. JAMA Netw Open. 2020 May 1;3(5):e205202. doi: 10.1001/jamanetworkopen.2020.5202.</citation>
    <PMID>32437574</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholesterol</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>MICT</keyword>
  <keyword>MIIT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

